Amphetamine is a central nervous system stimulant sold in the U.S. under 4 brand and generic names, for attention deficit disorder with hyperactivity and narcolepsy. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Amphetamine Sulfate (application ANDA213980). Other amphetamine products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Regardless of indication, amphetamine should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of resulting insomnia. Narcolepsy Usual dose is 5 to 60 milligrams per day in divided doses depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, amphetamine sulfate tablets may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia) dosage should be reduced. Give the first dose on awakening; additional doses (5 or 10 mg) at intervals of 4 to 6 hours. Attention Deficit Disorder with Hyperactivity Not recommended for children under 3 years of age. In children from 3 to 5 years of age , start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained. In children 6 years of age or older , start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal…
Cardiovascular Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. Central Nervous System Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and verbal tics and Tourette's syndrome. Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects when amphetamines are used for other than the anorectic effect. Allergic Urticaria Endocrine Impotence, changes in libido, and frequent or prolonged erections. Musculoskeletal Rhabdomyolysis
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Tablet | Generic | $479 | View → | |
| 2 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| Lannett;0791 | 2.5 mg / 2.5 mg / 2.5 mg / 2.5 mg | blue, blue | capsule | — |
| LANNETT;0790 | 1.25 mg / 1.25 mg / 1.25 mg / 1.25 mg | blue, white | capsule | — |
| Lannett;0792 | 3.75 mg / 3.75 mg / 3.75 mg / 3.75 mg | white, blue | capsule | — |
| Lannett;0793 | 5 mg / 5 mg / 5 mg / 5 mg | orange, orange | capsule | — |
| Lannett;0794 | 6.25 mg / 6.25 mg / 6.25 mg / 6.25 mg | white, orange | capsule | — |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
The elimination half-life of amphetamine is about 10 to 11 hours for d-amphetamine (range 9.8 to 11 hours) and about 12 to 14 hours for l-amphetamine (range 11.5 to 13.8 hours) in healthy adults. These are elimination half-lives for the two amphetamine isomers themselves; l-amphetamine clears more slowly than d-amphetamine. Elimination speeds up in acidic urine and slows in alkaline urine, and can be prolonged by kidney or liver problems.
Adderall (dextroamphetamine and amphetamine) CII tablet — FDA/DailyMed label, Clinical Pharmacology ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Known hypersensitivity to amphetamine products. • During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) (see WARNINGS ).
MAO inhibitors - MAOI antidepressants, as well as a metabolic of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results. Serotonergic Drugs - The concomitant use of amphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during amphetamine sulfate tablets initiation or dosage increase. If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the concomitant serotonergic drug(s) (see WARNING and PRECAUTIONS ). CYP2D6 Inhibitors - The concomitant use of amphetamine sulfate and CYP2D6 inhibitors may increase the exposure of amphetamine sulfate compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during amphetamine sulfate initiation and after a dosage increase. If serotonin syndrome occurs, discontinue amphetamine sulfate and the CYP2D6 inhibitor (see WARNING , OVERDOSAGE ).…
| 70/100 |
| Prescription |
| Tablet |
| Generic |
| $479 |
| View → |
| 3 | Not yet rated | Prescription | Suspension | Generic | $479 | View → |
| 4 | Not yet rated | Prescription | Tablet | Generic | $479 | View → |
| Lannett;0795 | 7.5 mg / 7.5 mg / 7.5 mg / 7.5 mg | orange, white | capsule | — |
|---|
| AMG;277 | 1.25 mg / 1.25 mg / 1.25 mg / 1.25 mg | white, green | capsule | — |
|---|
| AMG;278 | 2.5 mg / 2.5 mg / 2.5 mg / 2.5 mg | green | capsule | — |
|---|
| G454 | 5 mg / 5 mg / 5 mg / 5 mg | brown, brown | capsule | — |
|---|
| G456 | 7.5 mg / 7.5 mg / 7.5 mg / 7.5 mg | brown, brown | capsule | — |
|---|
| u;31 | 7.5 mg / 7.5 mg / 7.5 mg / 7.5 mg | orange | round | — |
|---|
| G453 | 3.75 mg / 3.75 mg / 3.75 mg / 3.75 mg | turquoise, white | capsule | — |
|---|